American Society of Hematology. (2017).
FDA Removes Risk Evaluation Management Strategies (REMS) for ESAs.
Retrieved from https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2017/fda-removes-risk-evaluation-management-strategies-rems-for-esas.
American Society of Hematology.
"FDA Removes Risk Evaluation Management Strategies (REMS) for ESAs." Hematology.org.
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2017/fda-removes-risk-evaluation-management-strategies-rems-for-esas
(label-accessed April 26, 2024).
"American Society of Hematology."
FDA Removes Risk Evaluation Management Strategies (REMS) for ESAs, 26 Apr. 2024 ,
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2017/fda-removes-risk-evaluation-management-strategies-rems-for-esas.
